Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status
DTIL(NASDAQ:DTIL) DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will be issued U.S. Patent No. 12,410,418 by the U.S. Patent and Trademark Office on September 9, 2025, titled “Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B Virus genome.” The compos
Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update
DTILDURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. “Our team continues to be very disciplined about executing our plans and is making strong progress advancing our clinical stage PBGENE-HBV program whil
Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B
DTILDURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, announced ELIMINATE-B results as of the data cutoff of July 28, 2025. Data include completed Cohort 1 (dosed at 0.2 mg/kg), the lowest dose level of the ELIMINATE-B trial, and initial safety data from Cohort 2 (dosed at 0.4 mg/kg). The ELIMINATE-B trial is designed
Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025
DTILDURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the second quarter 2025 and provide a business update on August 7, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving lif
HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
DTILPrecision BioSciences Q1 EPS $(2.21) Misses $(1.72) Estimate, Sales $29.00K Miss $5.00M Estimate
DTILPrecision BioSciences Accelerates Development Of First-in-Class In Vivo Gene Editing Therapy PBGENE-DMD For Duchenne Muscular Dystrophy Targeting Exons 45–55 Hot Spot, IND/CTA Submission Planned For 2025 And Clinical Data Expected In 2026
DTILUncovering Potential: Precision BioSciences's Earnings Preview
DTILPrecision BioSciences Reveals Presentation Of Initial Safety Data From Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV At 2025 European Association For Study Of Liver Congress (EASL)
DTILiECURE Announces It Will Present Initial OTC-HOPE Clinical Data of ECUR-506 In Ornithine Transcarbamylase Deficiency At American Society of Gene and Cell Therapy Annual Meeting May 12 – 17, 2025 In New Orleans
DTILPrecision BioSciences Announced That Five Abstracts Detailing Precision's Wholly Owned Or Partnered Programs Have Been Accepted For Presentation At The American Society Of Gene And Cell Therapy Annual Meeting Being Held May 13-17, 2025, In New Orleans, L
DTIL12 Health Care Stocks Moving In Tuesday's Pre-Market Session
DTILPrecision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, A Gene Editing Program To Cure Chronic Hepatitis B
DTILHC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
DTILAs Of December 31, 2024, Precision BioSciences Had Approximately $108.5M In Cash, Cash Equivalents, And Restricted Cash, With Expected Cash Runway Into The Second Half Of 2026
DTILPrecision BioSciences Q4 2024 GAAP EPS $(2.22) Misses $(1.96) Estimate, Sales $638.00K May Not Be Comparable To $4.28M Estimate
DTILPrecision BioSciences To Present Preclinical Safety And Efficacy Data For PBGENE-HBV At Global Hepatitis Summit 2025 On Mar. 21
DTILAssessing Precision BioSciences: Insights From 4 Financial Analysts
DTILHC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
DTILPrecision BioSciences Presents Preclinical Data For Its PBGENE-DMD Development Program For Treatment Of Duchenne Muscular Dystrophy
DTILPrecision BioSciences Achieves Regulatory Milestone As FDA Clears IND For First-in-Class PBGENE-HBV Gene Editing Therapy For Chronic Hepatitis B
DTILPrecision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate
DTILPrecision BioSciences reports early PBGENE-HBV trial data showing safety and antiviral activity in chronic Hepatitis B patients, with more results expected in 2025.
HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
DTILPrecision Biosciences Announced Initial Results From The First Administration Of Pbgene-hbv In Cohort 1, The Lowest Dose Level Of The Eliminate-b Trial
DTILPrecision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst
DTILPrecision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV program-driven stock growth.
HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
DTILBMO Capital Upgrades Precision BioSciences to Outperform, Maintains Price Target to $34
DTILPrecision Biosciences' Partner iECURE Has Reported Clinical Efficacy And Safety Data In The First Patient Dosed With ECUR-506 In The Phase 1/2 OTC-HOPE Study
DTILPrecision Biosciences Plans To Present Preclinical Data Supporting Advancement Of PBGENE-HBV Into Clinical Development, Company Says It Will Also Outline Design Of Its First-in-human Study, ELIMINATE-B In Patients With Chronic Hepatitis B
DTILPrecision BioSciences Q3 2024 GAAP EPS $(2.25), Inline, Sales $576.000K Miss $6.356M Estimate
DTILHC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
DTIL